Use of fused heteroaromatic pyrrolidones for treatment and prevention of diseases in animals

A method for the treatment and/or prophylaxis of allergic and/or inflammatory diseases in domestic animals and/or in farm animals in need thereof comprising administering to the animal an effective amount of the compound of the general formula (I)

• wherein:
• G is selected from N and C(R5);
• L1 and L2 are each independently selected from —NH— and a bond;
• R1 and R2 are each independently selected from hydrogen, halogen, C1-3-alkyl, and C1-3-halogenoalkyl having 1 to 5 halogen atoms, or R1 and R2, together with the atom to which they are attached, form a C3-6-cycloalkyl;
• R3 is selected from C2-6-alkyl, C3-8-cycloalkyl, C2-5-heterocyclyl, and C1-9-heteroaryl, each optionally substituted with one to five substituents independently selected from halogen, oxo, —NO2, —CN, R6 and R7;
• R4 is selected from C3-8-cycloalkyl, C2-5-heterocyclyl, C6-14-aryl and C1-9-heteroaryl, each optionally substituted with one to five substituents independently selected from halogen, oxo, —CN, R6 and R7;
• R5 is selected from hydrogen, halogen, —CN, C1-4-alkyl, C2-4-alkenyl, C2-4-alkynyl, C2-5-heterocyclyl, C1-5-heteroaryl, and R10, wherein the alkyl, alkenyl, alkynyl moieties are each optionally substituted with one to five substituents independently selected from halogen, —CN, oxo, and R10, and wherein the heterocyclyl moiety has 3 to 6 ring atoms and the heteroaryl moiety has 5 or 6 ring atoms, and the heterocyclyl and heteroaryl moieties are each optionally substituted with one to four substituents independently selected from halogen, —NO, —CN, C1-4-alkyl, C2-4-alkenyl, C2-4-alkynyl, C1-4-halogenoalkyl having 1 to 5 halogen atoms, and R10;
• each R6 is independently selected from —OR8, —N(R8)R9, —NR8C(O)R9, —C(O)R8, —C(O)OR8, —C(O)N(R8)R9, —C(O)N(R8)OR9, —C(O)N(R8)S(O)2R9, —N(R8)S(O)2R9, —S(O)nR8, and —S(O)2N(R8)R9;
• each R7 is independently selected from C1-6-alkyl, C2-6-alkenyl, C2-6-alkynyl, C3-6-cycloalkyl-(CH2)m-, C6-14-aryl-(CH2)m-, C2-5-heterocyclyl-(CH2)m-, and C1-9-heteroaryl-(CH2)m-, each optionally substituted with one to five substituents independently selected from halogen, oxo, —CN, C1-6-alkyl, C1-6-halogenoalkyl having 1 to 5 halogen atoms, and R10;
• each R8 and R9 is independently selected from hydrogen or from C1-6-alkyl, C2-6-alkenyl, C2-6-alkynyl, C3-6-cycloalkyl-(CH2)m-, C6-14-aryl-(CH2)m-, C2-5-heterocyclyl-(CH2)m- and C1-9-heteroaryl-(CH2)m-, each optionally substituted with one to five substituents independently selected from halogen, oxo, —NO2, —CN, C1-6-alkyl, C1-6-halogenoalkyl having 1 to 5 halogen atoms, and R10;
• each R10 is independently selected from —OR11, —N(R)R12, —N(R11)C(O)R12, —C(O)OR11, —C(O)N(R11)R12, —C(O)N(R11)OR12, —C(O)N(R11)S(O)2R12, —NR11S(O)2R12, —S(O)nR11, and —S(O)2N(R11)R12,
• each R11 and R12 is independently selected from hydrogen and C1-6-alkyl;
• each n is independently selected from 0, 1 and 2;
• and
• each m is independently selected from 0, 1, 2, 3, and 4;
• wherein each of the aforementioned heteroaryl moieties has one to four heteroatoms independently selected from N, O, and S, and each of the aforementioned heterocyclyl moieties is saturated or partially unsaturated and has one or two heteroatoms independently selected from N, O, and S;
• and the diastereomers, enantiomers, salts, solvates or solvates of the salts thereof, wherein the inflammatory disease is atopic dermatitis, Flea Allergy Dermatitis, inflammatory pain, non-infectious recurrent airway disease, insect hypersensitivity, asthma, respiratory disease, mastitis or endometritis.